Suven Life Sciences allots 1.85 crore shares via warrant conversion, raises Rs 249 crore

Warrants ConvertedFund Raising View source PDF Explain this filing

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹317.50

prior close

₹322.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.0%+2.2% vs market

Healthcare Research Analytics & Technology peers, median of 5sector+0.0%+0.2% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 0.2 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.8

15m

+0.8

30m

+2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2-2.0+2.2+0.0+0.2

Next day

+10.2-0.1+10.4+1.0+9.2

+12.3+1.2+11.0+2.6+9.7

+13.1+1.4+11.7+0.5+12.6

+9.9+0.4+9.6-0.1+10.0

+12.5+1.0+11.5+1.6+10.9

+2.2-0.5+2.7-1.1+3.3

15d

-1.5-0.6-0.9-2.0+0.6

+5.2+3.4+1.8-2.0+7.2

+16.5+6.0+10.5+13.4+3.1

-9.5+1.1-10.6+0.2-9.7

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suven Life Sciences allotted 1,85,70,133 equity shares at Rs 134 each to 17 non-promoter entities upon conversion of warrants, raising Rs 248.84 crore. Paid-up capital rises to 28,25,62,686 shares. Board also re-appointed Dr. Vajja Sambasiva Rao as Independent Director for 5 years from Jan 2027 and approved Singapore wholly owned subsidiary Suven Neurosciences Pte. Ltd. for neurological therapeutics with USD 100 million investment.

Likely market impact

Slight dilution for shareholders but company gets Rs 249 crore cash. Singapore unit signals global expansion into neurological drugs.